ArticleGenome research2019
The circular RNome of primary breast cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Genome research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 3 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- Clinicopathologic significance and prognostic value of circRNAs in osteosarcoma: a systematic review and meta-analysis.Journal of orthopaedic surgery and research · 2021Pooled it
- The Regulation Network and Clinical Significance of Circular RNAs in Breast Cancer.Frontiers in oncology · 2021Pooled it
- Circular RNA profiling facilitates the diagnosis and prognostic monitoring of breast cancer: A pair-wise meta-analysis.Journal of clinical laboratory analysis · 2021Pooled it
- Circular RNA as emerging precision therapeutics: from RNA regulation to peptide translation.Precision clinical medicine · 2026Review
- Detection of Candidate Circular RNAs to Monitor Anti-Hormonal Response in the Mammary Gland.bioRxiv : the preprint server for biology · 2026Article
- CircATP5C1 promotes triple-negative breast cancer progression by binding IGF2BP2 to modulate CSF-1 secretion.Cancer biology & therapy · 2025Article
- Circular RNAs orchestrating breast cancer hallmarks: bridging tumor biology and therapy resistance.Functional & integrative genomics · 2025Review
- CircCDYL Association With hnRNPL Modulates CDYL Isoform Switching in Breast Cancer Cells.Cancer science · 2025Article
- Tumor Microenvironment: Recent Advances in Immunotherapies of Pancreatic Cancer.Medicina (Kaunas, Lithuania) · 2025Review
- Direct circMAN1A2(2,3,4,5)-CENPB mRNA interaction regulates cell proliferation and cancer progression.Nature communications · 2025Article
- Genome-wide characterization of circular RNAs in three rat models of pulmonary hypertension reveals distinct pathological patterns.BMC genomics · 2025Article
- CircRNAs: a novel potential strategy to treat breast cancer.Frontiers in immunology · 2025Review
- Role of circular RNAs in preeclampsia (Review).Experimental and therapeutic medicine · 2024Review
- Circular RNA as a source of neoantigens for cancer vaccines.Journal for immunotherapy of cancer · 2024Article
- Review
- Perspectives of circular RNAs in diabetic complications from biological markers to potential therapeutic targets (Review).Molecular medicine reports · 2023Article
- Regulation of Notch1 Signalling by Long Non-Coding RNAs in Cancers and Other Health Disorders.International journal of molecular sciences · 2023Review
- Evaluation of Circ_0000977-Mediated Regulatory Network in Breast Cancer: A Potential Discriminative Biomarker for Triple-Negative Tumors.Biochemical genetics · 2023Article
- Increased plasma levels of circPTP4A2 and circTLK2 are associated with stroke injury.Annals of clinical and translational neurology · 2023Article
- Circ_0124055 promotes the progression of thyroid cancer cells through the miR-486-3p/MTA1 axis.Journal of endocrinological investigation · 2023Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
41 authors at 20 institutions in 10 countries.
Marcel SmidErasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.ORCID 0000-0003-0605-1901
Saskia M WiltingErasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.
Katharina UhrErasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.
F Germán Rodríguez-GonzálezErasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.
Vanja de WeerdErasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.
Wendy J C Prager-Van der SmissenErasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.
Michelle van der Vlugt-DaaneErasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.
Anne van GalenErasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.
Serena Nik-ZainalWellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom.
Adam ButlerWellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom.
Sancha MartinWellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom.
Helen R DaviesWellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom.
Johan StaafDivision of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, SE-223 81 Lund, Sweden.
Marc J van de VijverDepartment of Pathology, Academic Medical Center, 1105AZ Amsterdam, the Netherlands.
Andrea L RichardsonDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.
Gaëten MacGroganDépartement de Biopathologie, Institut Bergonié, CS 61283 33076 Bordeaux, France.
Roberto SalgadoBreast Cancer Translational Research Laboratory, Université Libre de Bruxelles, Institut Jules Bordet, B-1000 Brussels, Belgium.
Gert G G M van den EyndenDepartment of Pathology/TCRU GZA, 2610 Antwerp, Belgium.
Colin A PurdieDepartment of Pathology, Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom.
Alastair M ThompsonDepartment of Pathology, Ninewells Hospital and Medical School, Dundee DD1 9SY, United Kingdom.
Carlos CaldasCancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, United Kingdom.
Paul N SpanDepartment of Radiation Oncology, and Department of Laboratory Medicine, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands.
Fred C G J SweepDepartment of Laboratory Medicine, Radboud University Medical Center, 6525GA Nijmegen, the Netherlands.
Peter T SimpsonCentre for Clinical Research, Faculty of Medicine, The University of Queensland, 4029 Brisbane, Australia.
Sunil R LakhaniCentre for Clinical Research, Faculty of Medicine, The University of Queensland, 4029 Brisbane, Australia.
Steven Van LaereCenter for Oncological Research, University of Antwerp, 2610 Antwerp, Belgium.
Christine DesmedtBreast Cancer Translational Research Laboratory, Université Libre de Bruxelles, Institut Jules Bordet, B-1000 Brussels, Belgium.
Angelo ParadisoIstituto Tumori G Paolo II, IRCCS, 70124 Bari, Italy.
Jorunn EyfjordCancer Research Laboratory, Faculty of Medicine, University of Iceland, 101 Reykjavik, Iceland.
Annegien BroeksThe Netherlands Cancer Institute, 1066CX Amsterdam, the Netherlands.
Anne Vincent-SalomonInstitut Curie, Department of Pathology and INSERM U934, 75248 Paris Cedex 05, France.
Andrew P FutrealDepartment of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas 77230, USA.
Stian KnappskogDepartment of Clinical Science, University of Bergen, 5020 Bergen, Norway.
Tari KingMemorial Sloan Kettering Cancer Center, New York, New York 10065, USA.
Alain ViariSynergie Lyon Cancer, Centre Léon Bérard, Lyon Cedex 08, France.
Anne-Lise Børresen-DaleDepartment of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, The Norwegian Radiumhospital, 0310 Oslo, Norway.
Hendrik G StunnenbergDepartment of Molecular Biology, Faculty of Science, Radboud Institute for Molecular Life Sciences, Radboud University Nijmegen, 6525GA Nijmegen, the Netherlands.
Mike StrattonWellcome Trust Sanger Institute, Hinxton, Cambridge CB10 1SA, United Kingdom.
John A FoekensErasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.
Anieta M SieuwertsErasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.
John W M MartensErasmus MC Cancer Institute and Cancer Genomics Netherlands, University Medical Center Rotterdam, Department of Medical Oncology, 3015GD Rotterdam, the Netherlands.
Erasmus MC Cancer Institute · NLWellcome Sanger Institute · GBRadboud University Nijmegen · NLNinewells Hospital · GBThe University of Queensland · AUUniversité Libre de Bruxelles · BEAmsterdam UMC Location University of Amsterdam · NLBrigham and Women's Hospital · USCambridge University Hospitals NHS Foundation Trust · GBHaukeland University Hospital · NOInserm · FRInstitut Bergonié · FRInstitut Jules Bordet · BEInstitut national de recherche en sciences et technologies du numérique · FRIstituto Tumori Bari · ITLund University · SEMemorial Sloan Kettering Cancer Center · USOslo University Hospital · NOThe Netherlands Cancer Institute · NLThe University of Texas MD Anderson Cancer Center · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTissue and Pathology CoreP50CA168504 · NCI · DANA-FARBER CANCER INST · PI MYLES A BROWN · 2013 to 2026
$30.1MCancer Research UK 16942Cancer Research UK 22932Cancer Research UK 23433Cancer Research UK 23916Cancer Research UK 27815NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA168504Wellcome TrustWellcome Trust 077012/Z/05/ZWellcome Trust WT100183MA
Abstract
Circular RNAs (circRNAs) are a class of RNAs that is under increasing scrutiny, although their functional roles are debated. We analyzed RNA-seq data of 348 primary breast cancers and developed a method to identify circRNAs that does not rely on unmapped reads or known splice junctions. We identified 95,843 circRNAs, of which 20,441 were found recurrently. Of the circRNAs that match exon boundaries of the same gene, 668 showed a poor or even negative (
Indexed as
Biomarkers, TumorBreast NeoplasmsCarrier ProteinsCREB-Binding ProteinFemaleHumansLymphatic MetastasisMCF-7 CellsRepressor ProteinsRNARNA, CircularTranscriptomeBiomarkers, TumorCarrier ProteinsCNOT2 protein, humanCREB-Binding ProteinCREBBP protein, humanRepressor ProteinsRERE protein, humanRNARNA, Circular
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.